Thermo Fisher Bioproduction Solutions

  1. From Process Development To QC—Optimize Your mAbs Workflow 5/29/2026

    See how integrated analytical capabilities help improve visibility across mAb workflows, enabling faster decisions, stronger process control, and reliable quality outcomes from development through QC.

  2. CHO Residual DNA Quantitation 5/29/2026

    Highly sensitive detection of trace DNA impurities supports safer manufacturing. Combining rapid workflows, strong specificity, and reliable recovery from complex samples enables confident monitoring.

  3. Leading The Way In Rapid Quantitation Of Host Cell DNA 5/29/2026

    Accurate, high-sensitivity quantitation of residual host cell DNA becomes faster and more consistent with integrated qPCR, automated prep, and broad assay coverage—helping streamline workflows.

  4. Advancing Cell Therapy With The CTS DynaCellect Magnetic Separation System 4/21/2026

    Closed, automated T cell isolation with greater than 85% efficiency and greater than 96% purity is now achievable in 70 to 100 minutes, with cGMP-ready scalability from research to clinical manufacturing.

  5. Cell Therapy: T Cell Isolation From Whole Blood 4/21/2026

    Whole blood offers a faster, lower-cost starting material for T cell isolation and CTS Detachable Dynabeads CD4/CD8 with the DynaCellect System make it a viable, cGMP-aligned option without preprocessing.

  6. Cell Therapy Selection Guide: Connected From Activation To Expansion 4/21/2026

    Active bead release gives manufacturers precise control over T cell isolation timing, phenotype preservation, and workflow efficiency, eliminating multi-day passive dissociation delays.

  7. Integrated T Cell Activation: Soluble DynActivator CD3/CD28 Prototype 4/21/2026

    Bead-free T cell activation is now achievable with a soluble, GMP-compliant format that supports up to 1.5 billion cells per vial, decouples activation from isolation, and removes with a simple cell wash.

  8. Dynabeads CD3 Depletion Prototype Supporting Solutions From Development To Delivery 4/21/2026

    Residual CD3+ cells shouldn't be the bottleneck in your allogeneic therapy workflow. This prototype achieves <0.5% residual T cells at commercial-scale processing capacity.

  9. Helping Enhance Yield And Purity Of Gene Therapy Capture And Polish Resins 3/12/2026

    Explore how strategic resin and buffer selection enhances AAV purification efficiency, from affinity capture that reduces processing steps to anion exchange methods that separate full capsids.

  10. Helping Enhance Yield And Purity Of mAb Capture And Polish Resins 3/12/2026

    Learn how optimized resin and buffer combinations improve mAb purification efficiency, helping you achieve stringent quality standards while extending resin lifetime and reducing costs.